Vivimed Labs Mascarene is the holding entity of the company’s API (active pharmaceutical ingredient) business, UQUIFA. Hyderabad-based Vivimed Labs had acquired UQUIFA for $55 million in 2011.
UQUIFA accounts for almost 60 per cent of the company’s total consolidated revenues and a higher proportion of the reported EBITDA.
The company had earlier received $42.5 million from OrbiMed Asia in September 2017. At the time, Vivimed had said that the proceeds of the fundraise would be used by the company mainly to reduce its debt and optimise capital structure at the parent entity level, and to invest in the API business for capacity augmentation and organic growth.
“The proceeds of this additional investment by OrbiMed Asia will be utilised to drive business growth, and increase the company’s profitability by organic and inorganic growth opportunities,” said Saurabh Gurnurkar, executive director, UQUIFA.
OrbiMed, with over $14 billion in assets under management, recently closed its third Asia private equity fund with $551 million in capital commitments. The new fund will invest across the Asian healthcare industry, with a focus on growth-stage product and services oriented companies in China and India.
Vivimed has manufacturing footprint across India, Europe and North America across its line of businesses and employs close to 2,000 personnel across the world. The company reported sales of about Rs 15 billion for the financial year ended March 31, 2017.